Arcutis Announces Publication Of Positive Data From INTEGUMENT-PED Trial Evaluating ZORYVE
Neutral
0.5
(RTTNews) - Arcutis Biotherapeutics, Inc.?(ARQT), Monday announced that Pediatric Dermatology published online positive results from INTEGUMENT-PED, the pivotal phase 3 randomized vehicle-controlled trial evaluating the efficacy and safety of?ZORYVE (roflumilast) cream 0.05%?as a
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
